-
South Korea court gives Unification Church leader 2 years prison
-
Nepal recovers bodies but presses on for trapped tunnel workers
-
US hosts G20 finance talks with growth, Iran pressure on agenda
-
Grand Canyon flash flood leaves one dead, around 15 missing
-
African players in Europe: Wissa flick seals Newcastle victory
-
Venus Williams falls at first hurdle in US Open
-
Venice film preview: Clooney, Oasis and Musk
-
At least five leaders skip annual Pacific Islands summit
-
Poorly Djokovic crashes out of US Open first round
-
I.Coast home-hunters' saga highlights Africa housing crunch
-
Djokovic falls in US Open first round, earliest Grand Slam exit in 20 years
-
At least five leaders to skip annual Pacific Islands summit
-
Chinese guitar capital's stairway to export heaven
-
Latest developments in the US-Iran war
-
Stocks drop as Warsh fans US rate hike bets, crude up on US-Iran strikes
-
Nepal buries dead as rescuers seek thousands missing
-
Injuries cloud tennis as US Open gets under way
-
From Montecito to the Cotswolds: Harry and Meghan eye new UK home
-
Iran retaliates after first US strikes in a month
-
Russia's Putin and China's Xi to attend summit in Kyrgyzstan
-
Itauma says 'I'll be back' after bruising heavyweight title loss
-
John Ternus to lead Apple into the age of AI
-
Brilliant Palou clinches fourth straight IndyCar crown
-
Trump calls for 'punishment' of NBC reporter
-
EN China XLX Announces 2026 Interim Results
-
US strikes Iran for first time in a month, Tehran retaliates
-
About 15 people missing after Grand Canyon flash flood
-
Yin holds off Kim to win sixth LPGA title, end title drought
-
Medvedev advances without drama at US Open
-
Top-ranked Scheffler storms to PGA Tour Championship win
-
Calhanoglu fires Inter to nervy Cagliari win, Como stun Napoli
-
Root urges England to be 'grown-ups' after Pakistan series win
-
Monaco beat Marseille to go top, Rosenior's Paris FC thump Nice
-
Google Maps renames Lake Ontario 'Lake America' in US -- but not Canada
-
Pegula shakes off nerves in US Open first-round win
-
Aaron Donald ends retirement to rejoin Rams: team
-
FIFA president Infantino 'must go', says ex-UEFA boss Platini
-
Niamey back to normal after soldiers' mutiny
-
England v Pakistan second Test: Three talking points
-
Niger mutiny suppressed, but questions remain over junta's cohesion
-
Rashford's return 'fantastic' for Man Utd, says Carrick
-
Como spoil Allegri's Napoli home debut
-
At least 8 die, more missing, as ferry capsizes off Northern Cyprus
-
Cruz Beckham Performs at Leeds Festival Following Family Support at Reading
-
Pegula shakes off nerves, Ruse in US Open first-round win
-
Fernandes hat-trick inspires Man Utd rout of Ipswich
-
Fernandes treble inspires Man Utd rout, Chelsea beat Brighton in thriller
-
Suzuki sends 'perfect' Freiburg past Bremen, Schalke lose
-
September smartphone calendar spans Apple, Poco, Vivo and Xiaomi
-
Realme P4s, iQOO Z11 and Nothing Phone 4b compared
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 at 10:00 AM ET.
CASI will also host one-on-one meetings with investors at the conference.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.
More information on CASI is available at www.casipharmaceuticals.com.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
[email protected]
SOURCE: CASI Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
R.Garcia--AT